Article ID Journal Published Year Pages File Type
10484977 Value in Health 2014 9 Pages PDF
Abstract
Based on an indirect comparison of randomized trials, bazedoxifene is expected to have at least a comparable RRR of NVF as alendronate, ibandronate, and risedronate in women with higher risk of postmenopausal osteoporosis.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
Bazedoxifene versus Oral Bisphosphonates for the Prevention of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture: A Network Meta-Analysis
Authors
, , , , , , , , ,